BioSpace News Archive

BD, a leading global medical technology company, announced that it has completed its spinoff of Embecta Corp., which holds BD’s former Diabetes Care business and is now one of the largest pure-play diabetes management companies in the world.

Cardinal Health plans to release third-quarter financial results for its fiscal year 2022 on May 5 prior to the opening of trading on the New York Stock Exchange.

NovaBay® Pharmaceuticals, Inc., a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the launch of Hydrating Cleansing Oil as the newest product under the DERMAdoctor Calm Cool + Corrected brand.

Siena, 1April 2022 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics, provides an update regarding the Company’s full year 2021 results and recent corporate developments.

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provide painless and precise injections, provided a business update and announced financial results for the full year ending December 31, 2021.

Amarin Corporation plc announced in vitro research results suggesting that Eicosapentaenoic Acid, in combination with widely prescribed statins, contributed to a reduction in lipid oxidation in membranes in a manner that may be enhanced with the use of these statins.

ADMA Biologics, Inc. announced a poster presentation and exclusive Key Opinion Leader symposium by nationally recognized clinical experts on the management of respiratory viral infections and real-world experience with ADMA’s ASCENIV, a U.S. Food and Drug Administration -approved intravenous immunoglobulin product with a unique composition.

Altimmune, Inc. today announced that it has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide 1 in subjects with obesity or overweight.

Aravive, Inc. announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules with a single healthcare-focused institutional investor and Eshelman Ventures, LLC.

Petros Pharmaceuticals, Inc. today announces financial results for the fiscal year ended December 31, 2021.